

IceCure

Freezing Cancer in its Tracks

ProSense® is the first and only medical device to be granted U.S. FDA marketing authorization for the local treatment of low-risk breast cancer with endocrine therapy

(Nasdaq: ICCM)

icecure-medical.com

July 2026

Forward Looking Statements; Disclaimer

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure Medical Ltd. (“IceCure”, “IceCure Medical” or the “Company”) is using forward looking statements in this presentation when it discusses: the expected growth of the tumor ablation market; the potential for ProSense to set a new standard of care; the Company’s post-market study plan and its support of ProSense commercial roll-out; that Terumo Corporation is expected to submit its request for breast cancer clearance to the Japanese Pharmaceuticals and Medical Devices Agency by the end of H1 2026; its cash position; business, regulatory, marketing and commercialization strategy; prospective regulatory approvals and the expected timing thereof for its various products worldwide; that the FDA 510(k) regulatory clearance for XSense and its commercialization may lead to new uses for certain other clinical indications; the prospective soft launch of XSense in the fourth quarter of 2026; the expected number of total breast cancer diagnoses in 2026; that cryoablation may require further clinical trial studies; that additional coverage is expected upon the establishment of the permanent CPT Category I code; that the Company anticipates greater market traction in the rest of the world based on positive U.S. ICE3 final results; that more data is expected with ongoing studies of ProSense in 2026; that there is a growing number of distribution partnerships with numerous recent regulatory approvals; and that the potential benefits and impact IceCure’s products could have on improving patient health care.

Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, please review the Company’s reports and other documents filed from time to time with the U.S. Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

This presentation does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company or any other entity, and nothing contained herein shall form the basis of or be relied on in connection with any action, contract, commitment or relating thereto or to the securities of the Company.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the presentation. The presentation has not been independently verified and will not be updated. The presentation, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results.

IceCure Corporate Overview

First-and-only solution with U.S. labeling for the minimally invasive local treatment of breast cancer

IceCure Poised To Disrupt Cancer Care

ProSense System

ONLY MIS cryoablation device in U.S. labeling for Breast Cancer with an 8+ year head start due to Special Controls protocol(1)
a $1.2bn+ TAM(2)

- **Employees:** 64 FTEs
- **Global Presence:** Regulatory approvals in 27 countries
- **Sales Infrastructure:** 12 reps & sales support personnel; 10 established global distributors and Terumo partnership in Japan
- **Manufacturing:** Established and ready to scale
- **Robust Intellectual Property:** 47 granted patents globally

Game-Changing Novel LN2 Cryoablation

- New class of cryoablation that overcomes legacy cryoablation challenges



(1) Includes "Special Controls" protocol providing significant competitive barrier to entry in US.
(2) Sources: World Health Organization and Annals of Breast Surgery. $1.2bn+ TAM assumes 690,000 annual incidence, disposable probe ASP of $1,750, and 1 disposable used per procedure. Note: TAM figure excludes contribution of capital equipment from TAM calculation.

Recent Achievements

- Reported 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
- American Society of Breast Surgeons (“ASBrS”) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
- U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
- Onboarding of medical centers in two new states in the U.S. now offer local breast cancer treatment with ProSense®
- Kidney Cancer: ProSense® Reports Nearly 90% Recurrence-Free Rate from ICESECRET Cryoablation Study

New Real-Life Testimonials



CBS NEWS

"A patient can resume activity very quickly and therefore it improves both the physical and emotional aspects of diagnosis and treatment" – Dr. Fine

REUTERS

(1) Dr.Fine holds restricted shares of IceCure.

Proven Leadership Team

Experienced management team with deep medtech expertise

Eyal Shamir, CEO

Over 15 years of experience as CEO of medical device companies (B-Cure Laser, Hanita Lenses etc.)

Meir Peleg, CFO

Over 20 years of financial leadership and deep capital markets experience as a seasoned public company CFO, with a unique background in software engineering

Shay Levav, COO

Over 20 years of experience in regulatory and quality assurance in the healthcare sector.

Merav Nir Dotan, VP Human Resources

Over 20 years of experience in human resources and organizational management

Ron Mayron, Chairman of the Board

Served for 20 years in several positions at Teva including as VP – Israel & Africa & CEO of Teva Israel

Shad Good, VP Sales North America

Nearly 20 years of medical device sales and leadership with experience in minimally invasive breast diagnostic and therapeutic systems

Tlalit Bussi Tel-Tzure, VP Business Development & Global Marketing

Over 15 years of experience in Sales, Business Development & Marketing in medical devices

The 100 Year De-Escalation Journey In Breast Cancer

Clinicians and patients have pursued a clinically effective breast preserving treatment option for >100 years

Radical Mastectomy → Modified Radical Mastectomy → Lumpectomy *(axillary dissection)* → Lumpectomy *(lymph node biopsy)* → ***Cryoablation***



Radical Mastectomy
Halstead 1890s



Modified Radical Mastectomy
Dyson & Patey 1948

Total Mastectomy + Radiation
McWhirter 1948



Lumpectomy with Axillary Dissection + Radiation

Late 1980s/1990s



Lumpectomy / Sentinel Lymph Node Biopsy

John Wayne Cancer Institute, 1991



Cryoablation

R W Rand 1985

UCLA School of Medicine

IceCure

Breast Cancer Represents a Massive TAM With Key Unmet Needs

As the only minimally invasive treatment approved with U.S. labeling for breast cancer, IceCure is positioned to penetrate one of the largest oncology segments in the U.S., including 2.3mm[(1)] new breast cancer patients globally

Annual New U.S. Patients



(1) https://www.who.int/news-room/fact-sheets/detail/breast-cancer
(2) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf
(3) https://www.oncologynurseadvisor.com/factsheets/lung-cancer-statistics/#:~:text=Of%20the%20estimated%20234%2C580%20new,3
(4) https://nmtracking.doh.nm.gov/dataportal/indicator/view/CancerIncidKidneyRP.Cnty.html#:~:text=Kidney%20cancer%20accounts%20for%20about%204%25%20of,and%20about%202.4%25%20of%20annual%20cancer%20deaths
(5) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/mr3-sex-cases-and-deaths-2024.pdf
(6) https://www.who.int/news-room/fact-sheets/detail/endometriosis

IceCure – Key Company Highlights

IceCure's novel labeling and cryoablation technology creates a significant commercial opportunity and positions IceCure to become the market leading platform in minimally-invasive cancer care

- Next-generation minimally-invasive LN2 cryoablation platform poised to disrupt cancer care
- Only cryoablation technology with breast cancer labeling potentially allowing for an 8+ year head start due to Special Controls protocol – a $1.2bn+ TAM
- Robust clinical dossier, regulatory approvals and operational footprint position IceCure for rapid commercialization
- Strong R&D pipeline to drive long-term growth into additional market opportunities, including renal denervation
- Highly attractive, rapid growth / high margin razor-razor blade financial profile
- Robust IP portfolio with 47 issued patents globally
- Highly experienced and capable medical technology management team

ProSense – IceCure's Disruptive LN2 Cryoablation Platform

Groundbreaking technology poised to drive the shift to minimally-invasive breast cancer treatment

ProSense System



FDA-Cleared & CE-Marked

IceCure's Flexible Business Model To Drive Adoption

Console related revenues

- ✓Sales of consoles
- ✓Consoles loaned for a minimum purchase of probes per month
- ✓Accessories

Probes and introducers

- ✓Recurring Revenue

Service & Maintenance

- ✓Recurring Revenue

Cryoablation Key Advantage – Patient Experience vs. Lumpectomy

Current standard-of-care, lumpectomy, presents a lengthy, stressful journey with anesthesia, recovery and high re-excision rates – impacting patient experience and outcomes



1. Pre-surgical screening / Medical Clearance

2. Fasting
Begins at midnight, anxiously await procedure in advance

3. Radiology
Patient starts day in radiology department to insert localization device

4. Pre-surgical Prep
Meet with surgeon and anesthesiologist

WAIT

5. Full Anesthesia
Lumpectomy procedure lasts 1-2 hours, tumor is surgically excised

6. Recovery Room
1 hour in recovery, waiting for anesthesia to wear off.
Patient may experience pain, nausea; need to be driven home

7. Recovery at Home
Pain control, potential continued nausea from anesthesia, higher risk of post-operative bleeding or seroma

8. Re-excision
14-20%(1) of patients may undergo re-excision after lumpectomy due to unclear margins

(1) Tamirisa et al, Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients, https://doi.org/10.1245/s10434-020-09370-0

Cryoablation Advantage – Patient Experience vs. Lumpectomy

Cryoablation offers a faster, less invasive procedure with no delays from prep or waiting, eliminates the need for general anesthesia and offers rapid same-day recovery times with low / insignificant re-excision rates



1. Pre-treatment screening

2. Breakfast
Enjoy a healthy breakfast

3. Option to drive yourself to cryoablation appt.

4. Pre-surgical Prep
Meet with surgeon and anesthesiologist

4. Cryoablation
- **Local anesthesia**
- **Small bandage** placed on insertion site
- **One hour** start to finish

5. Resume normal activities
start your journey towards being a breast cancer survivor

6. Recovery Room

7. Recovery at home

8. Re-excision

Source: Tamirisa et al, Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients https://doi.org/10.1245/s10434-020-09370-0

Clinical Validation – ICE3: Landmark Study For Cryoablation Of Breast Cancer

194 patient, open-label study across 19 sites of cryoablation with early-stage breast cancer

ICE3 was a 10-year investment that led to the only on-label minimally invasive treatment for breast cancer in the U.S.

Study Design Overview & Details

- Single-arm, open-label study evaluating the efficacy of cryoablation without lumpectomy on local and distant recurrence of early-stage breast cancer
- **194 patients** meeting eligibility received treatment per protocol
- **19 sites** across the United States, including such key sites as:
  - Columbia University / Presbyterian (NY)
  - Weill Cornell (NY)
  - Mount Sinai Beth Israel (NY)
  - CentraState Medical Center (NJ)
  - West Cancer Clinic (TN)

Primary Endpoint

- Local in **Ipsilateral Breast Tumor Recurrence (IBTR) rate at 6 months** post-cryoablation, followed by annual **follow-up for five years**

Key Secondary Endpoint

- Complete ablation of primary tumor (up to 5 years post-ablation)
- Improvement in patient QoL (NCCN DISTRESS THERMOTETER)
- Breast cosmetic satisfaction (up to 5 years post-ablation)
- Overall survival, disease-free survival and breast cancer survival (up to 5 years)
- Adverse events (up to two years for AEs and up to five years for SAEs)

Source: clinicaltrials.gov

ProSense Clinical Results vs. Current Gold Standard Lumpectomy

ProSense offers gold standard outcomes AND preserved breast cosmesis

ProSense vs. Lumpectomy Clinical Data

	Lumpectomy	IceCure[3]
Recovery Time	1 week or greater[1]	**24 hours**
Recurrence Rate	5-10% at 5 yrs.[1]	**4.3%** at 5 yrs.
Re-excision	14-20% of patients[2]	**No re-excision**
Survival Rate	95-98% at 5 yrs.[1]	**96.7%** at 5 yrs.
Adverse Events	Pain, infection & lymphedema[1]	**No major device-related adverse events**
Cosmetic Outcomes	Often suboptimal (varies by individual)	Satisfaction to date: **99.1% for patients** **97% for physicians**

ProSense vs. Lumpectomy Outcomes



Patient Outcome:
ProSense



Patient Outcome:
Lumpectomy

(1) U.S. FDA.
(2) Tamirisa et al, Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients https://doi.org/10.1245/s10434-020-09370-0
(3) ICE3 Trial results.

IceCure

Robust Body of Highly Supportive Clinical Studies In Breast Cancer To Drive Adoption

Large body of clinical studies supporting the first and only Breast Cancer labeling in the U.S. with over 1,500 patients treated across 17 clinical studies

	Study	Body Part	Trial Design	Started / Finished	Sites/Geographies	Key Takeaways
1.	**Ultrasound Guided Cryoablation of Fibroadenomas**	Breast	Single arm, open label	▪ April 2009-September 2012	▪ Czech Republic (1 site) ▪ Israel (1 site) ▪ Germany (2 sites)	▪ At one-year follow-up, no fibroadenomas in 93% of cases
2.	**Multi-Site Clinical Trial of the Cryoablation System ICE3 Study**	Breast	Single arm, open label	▪ May 2014-March 2024	▪ US (19 sites)	▪ Median follow-up period of 54.16 months with IBTR rate of 4.3% and survival rate of 96.7%
3.	**Independent Study – Kameda Medical Center**	Breast	Single arm, open label	▪ May 2012-Ongoing	▪ Japan (1 site)	▪ 600+ procedures performed in Japan ▪ Recurrence of tumor rate of less than 1%
4.	**Independent Study – St. Marianna University School**	Breast	Single arm, open label	▪ May 2018-May 2020	▪ Japan (1 site)	▪ 7 patients treated with breast tumors ≤ 1.5cm ▪ No evidence of malignancy after a two-year follow-up
5.	**Independent Study – Queen Mary Medical Center**	Breast	Single arm, open label	▪ November 2018-Ongoing	▪ Hong Kong (1 site) ▪ China (1 site)	▪ Treatment performed in 20 patients out of planned 150 ▪ Focus on PET/MRI imaging efficacy and safety in cryoablation
6.	**Independent Study – University Hospital Lucus Augusti**	Breast	Single arm, open label	▪ October 2023-Present	▪ Spain (1 site)	▪ 31 patients with early-stage breast cancer treated; 96.8% success rate
7.	**Independent Study – Universitaria Careggi**	Breast	Single arm, open label	▪ February 2024-Present	▪ Italy (1 site)	▪ 39 women with inoperable breast cancer treated ▪ Median tumor size reduction: 27.8% at 1 month, 100% at 12 months

FDA Post-Market Study Requirements & Design Elements

Rigorously designed post-market study aims to continue to build clinical validation in a commercial setting

Study Type	▪ Post-market surveillance study to produce additional clinical data collection and serve as active commercial sites for treatment
Centers	▪ **At least 30** sites across the U.S.
Study Size & Patient Population	▪ **~400** patients
Expected Initiation	▪ H2 2026
Expected Enrollment Timeline	▪ **20%** of subjects enrolled within **12 months**; **50%** of subjects enrolled within **18 months**; **100%** of patients enrolled within **36 months**
Co-Primary Endpoints	▪ **5-years IBTR rate**
Secondary Endpoints	▪ Time to recurrence / ipsilateral breast surgeries for treatment of residual/recurrent disease; disease-free survival and overall survival rates

IceCure – Poised to Drive Significant Revenue Growth

Key pieces in place to drive significant growth upon U.S. market entry in breast cancer

(1) Includes "Special Controls" protocol providing significant competitive barrier to entry in U.S.

U.S. Sales Strategy – Overview

IceCure's highly experienced Commercial leadership team will employ a well-validated model of selling via a highly compelling clinical + economic story with top sales reps and world class customer support

Sales Strategy
Attract top sales talent

Focused Customer Targeting
High volume breast surgeons, breast radiologists, interventional radiologists

World Class Customer Education
Robust landmark clinical data + obvious advantages of MIS cryoablation

Compelling Economics
Existing reimbursement, rapid ROI at low patient volumes, competitive marketing/patient capture

Invest In Our Sales Reps
Provide rep market leading training and assist with sales/ customer support

Leverage Existing Global Footprint & Distribution Relationships
Intelligently expand sales footprint

Well Understood Target Clinical Call Points For MIS Breast Cryoablation

Key call points in breast cancer will be breast surgeons and breast radiologists / interventional radiologists

Breast Surgeon:

Breast exams, risk assessment, treatment planning, surgery, post-treatment follow up

- **Hospitals** *(typically breast centers)*
- **Private practices or clinics**
- **Ambulatory surgery centers**

Breast Radiologist & IR:

Interpret screening and diagnostic images of the breast, perform biopsy and localization procedures, post-procedure follow up imaging

- **Hospitals** *(breast cancer or radiology dept.)*
- **Private practices** *(free standing imaging centers)*

Concentrated call point that only requires ~40 sales & marketing employees to fully commercialize

ProSense Delivers the Elusive ‘Quadruple Win’

ProSense offers clear benefits for patients, physicians, payors and hospital systems compared to lumpectomy

Patients

- ✓ **Minimally invasive**
- ✓ Cosmetically superior
- ✓ Safer, simpler, faster and with minimal-to-no pain
- ✓ Same-day recovery
- ✓ Preventing re-excision after lumpectomy[1],[2]

Physicians

- ✓ **Increased ROI**
- ✓ Faster – more patients
- ✓ Easy-to-use
- ✓ Low risk, safe procedure

Payors

- ✓ **Lower total cost vs. surgery** [3]
- ✓ Patient satisfaction
- ✓ Value-based care

Healthcare Systems

- ✓ **Less than an hour**[4]
- ✓ Patient/provider-preferred treatment
- ✓ Low risk, safe procedure
- ✓ No new infrastructure
- ✓ Environmentally & storage friendly

Liquid nitrogen offers maximum benefits to patients, physicians, insurers and healthcare systems

(1) Citation - Havel L, Naik H, Ramirez L, Morrow M, Landercasper J. Impact of the SSO-ASTRO Margin Guideline on Rates of Re-excision After Lumpectomy for Breast Cancer: A Meta-analysis. Ann Surg Oncol. 2019 May;26(5):1238-1244. doi: 10.1245/s10434-019-07247-5. https://pubmed.ncbi.nlm.nih.gov/30790112/
(2) Tamirisa et al, Impact of SSO-ASTRO “No Ink on Tumor” Guidelines on Reexcision Rates among Older Breast Cancer Patients, https://doi.org/10.1245/s10434-020-09370-0
(3) Wu, Xiao et al. “Cryoablation Versus Breast-Conserving Surgery for Early-Stage, Low-Risk Breast Cancer ≤ 1.5 cm: A Cost-Effectiveness Analysis.” Cardiovascular and interventional radiology vol. 49,2 (2026): 313-321. doi:10.1007/s00270-025-04269-3.
(4) ICE3 Study Results.

IceCure

IceCure – Leveraging Our Existing Global Infrastructure

27 global regulatory approvals and significant infrastructure in place for rapid scaling in breast cancer



Key Global Distribution Relationships

Izasa Medical by Palex

TERUMO Japan Distribution

EMIT

TuringMedical 图灵微创 · 智愈未来

KTR GROUP

MC MEDICAL

PES MED

NOVOMED

ABLATECH

Igiasi s.a

biomur Soluciones médicas

IceCure

Breast Cancer – Terumo Japan Agreement

Exclusive strategic distribution agreement with Terumo to accelerate commercialization of ProSense in Japan

For >6 years ProSense has been sold through a Private Import License – now leveraging an agreement with Terumo to expand distribution and acquire PMDA approval

$19.40bn[1] market cap
$6.99bn[1] annual revenue

91,916 new breast cancer cases in Japan in 2022[2]

- Total proceeds of $13.2mm for the initial term
  - ✓ $5mm for initial order and milestone-based payments
  - ✓ $4mm received
- Key terms:
  - ✓ Exclusive distribution of ProSense for breast cancer in Japan for 5 years post regulatory approval in Japan
  - ✓ Responsible for Japanese regulatory and reimbursement approvals
  - ✓ Terumo is expected to submit the request for breast cancer clearance to the Pharmaceuticals and Medical Devices Agency (PMDA) by the second half of 2026

(1) CapIQ as of February 13, 2026
(2) 392-japan-fact-sheet.pdf

Strong Support from Five Medical Societies And Leading KOLs

With a robust supportive clinical dossier and clear advantages for patients, IceCure has been able to garner support from the leading Medical Societies involved in breast cancer care as well as top KOL influencers

"Cryoablation is a safe, minimally invasive ablative procedure with acceptably low 5-year same breast recurrence similar to that of lumpectomy for similar patient populations." **Richard E. Fine, MD, FACS , Breast Surgeon** ***West Cancer Clinic, TN***[1]

"…**96.3% recurrence free rate** for those treated with ProSense® and endocrine therapy – that demonstrates the potential for cryoablation for small, low-risk breast cancer to be a safe and **effective primary treatment option** to surgical lumpectomy."
Kenneth R. Tomkovich, MD, Breast Radiologist, ICE3 Co-Primary Investigator ***Princeton Radiology, NJ***[2]

"Cryoablation is more minimally invasive than lumpectomy and **studies have shown similar if not improved outcomes - not just in regards to recurrence but also regarding the psycho-emotional aspect of breast cancer treatment**...I treated dozens of patients with early-stage breast cancer... They are thrilled with their cosmetic results, impressed with how little discomfort they experienced and quick return to work, family responsibilities and normal activity." **Cynthia Aks, MD, FACS, Breast Surgeon, OR**

"An advantage of the ProSense System compared to other ablation devices is that **the patient does not feel any pain during the procedure or afterwards**. Because we can easily check the ablation area and see the ice ball forming easily with CT or Ultrasound, we can be very safe in covering the tumor area need without harming any sensitive structures close to the target." **Franco Orsi, MD, Director of Interventional Oncology,** ***European Institute of Oncology, Milan, Italy***[3]

(1) Dr.Fine holds restricted shares of IceCure.
(2) Dr. Tomkovich has entered into a Consulting Agreement with IceCure.
(3) Dr. Orsi received compensation from IceCure related to attendance at conferences.

Key Medical Societies

THE AMERICAN SOCIETY OF Breast Surgeons
Society of Interventional Radiology
SIO Society of Interventional Oncology
SBI SOCIETY OF BREAST IMAGING SINCE 1985
RSNA Radiological Society of North America
IceCure

US Reimbursement Strategy

Category 3 reimbursement will support initial U.S. commercialization, with TPT less than 12 months away and a clear path to Category 1 reimbursement anticipated in early 2028

- **Customer Collateral Package: Complete**
  - Category 3 Code billing processes
- **Anticipated Increase Payment Assignment for Category 3 Code**
  - Extract data in June '26 → Window to submit July-September '26 → **Payment assignment updated in November '26**
- **Payor Outreach**
  - Focus on Medicare Advantage Plans
- **Pass Through Payment Assessment & Potential Implementation**
  - Assess increase in additional payment for new technology in outpatient settings
  - Applies to Medicare
  - Initial assessment Q4 2025 → Submitted Q4 2025 → **Estimated implementation anticipated Q1 2027**
- **Customer Support Program for Filing Claims**
  - Provide support/strategy resources to successfully file claims
  - Implemented Q1 2026
- **Start Transition to Category 1**
  - Potential start date of January 2028

IceCure: Pioneering a Disruptive, Minimally-Invasive Cancer Treatment Platform

Beyond breast cancer, IceCure has already had significant clinical success in other key cancer markets to address the broader $2.5bn[(1)] minimally invasive cancer treatment market

ProSense Platform Opportunity

Breast

- Received FDA clearance Q4 '25

Lung

- Independent Japan study 77-100% recurrence free

Kidney

- ICESECRET study 88.7% recurrence free

Bone

Liver

Endometriosis

(1) Interventional Oncology Devices Global Market Report 2024 from Research and Markets.

Thank You!

Eyal Shamir, CEO

E: investors@icecure-medical.com
T: +972-4-623-0333